Abstract
The aim of reverse pharmacognosy is to find new biological targets for natural compounds by virtual or real screening and identify natural resources that contain the active molecules. To demonstrate the applicability of this concept, we report here a study on εviniferin, an active ingredient for cosmetic development. Nevertheless, this natural substance is weakly defined in terms of biological properties. SELNERGY, an inverse docking computer software, was used to identify putative binding biological targets for εviniferin. Among the 400 screened proteins two targets were retained. For cosmetic application, cyclic nucleotide phosphodiesterase 4 (PDE4) was the most interesting candidate. Moreover, other PDE subtypes (1, 2, 3, 5 and 6) were not retained, indicating a selectivity for PDE4. The experimental binding tests on the 6 subtypes of PDE revealed a significant selectivity of εviniferin for the PDE4 subtype. This selectivity was confirmed by evaluation of εviniferin on the secretion of TNF-α and Interleukin-8. Our data demonstrated that εviniferin possesses anti-inflammatory properties by inhibiting PDE4 subtype. In conclusion, reverse pharmacognosy and its inverse docking component cannot only be integrated into a program for new lead discovery but is also a useful approach to find new applications for identified compounds.
Keywords: Inverse docking, cosmetics, cyclic nucleotide phosphodiesterases, viniferin, selnergy
Current Drug Discovery Technologies
Title: Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin
Volume: 2 Issue: 3
Author(s): Quoc-Tuan Do, Isabelle Renimel, Patrice Andre, Claire Lugnier, Christian D. Muller and Philippe Bernard
Affiliation:
Keywords: Inverse docking, cosmetics, cyclic nucleotide phosphodiesterases, viniferin, selnergy
Abstract: The aim of reverse pharmacognosy is to find new biological targets for natural compounds by virtual or real screening and identify natural resources that contain the active molecules. To demonstrate the applicability of this concept, we report here a study on εviniferin, an active ingredient for cosmetic development. Nevertheless, this natural substance is weakly defined in terms of biological properties. SELNERGY, an inverse docking computer software, was used to identify putative binding biological targets for εviniferin. Among the 400 screened proteins two targets were retained. For cosmetic application, cyclic nucleotide phosphodiesterase 4 (PDE4) was the most interesting candidate. Moreover, other PDE subtypes (1, 2, 3, 5 and 6) were not retained, indicating a selectivity for PDE4. The experimental binding tests on the 6 subtypes of PDE revealed a significant selectivity of εviniferin for the PDE4 subtype. This selectivity was confirmed by evaluation of εviniferin on the secretion of TNF-α and Interleukin-8. Our data demonstrated that εviniferin possesses anti-inflammatory properties by inhibiting PDE4 subtype. In conclusion, reverse pharmacognosy and its inverse docking component cannot only be integrated into a program for new lead discovery but is also a useful approach to find new applications for identified compounds.
Export Options
About this article
Cite this article as:
Do Quoc-Tuan, Renimel Isabelle, Andre Patrice, Lugnier Claire, Muller D. Christian and Bernard Philippe, Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin, Current Drug Discovery Technologies 2005; 2 (3) . https://dx.doi.org/10.2174/1570163054866873
DOI https://dx.doi.org/10.2174/1570163054866873 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Future of Collateral Artery Research
Current Cardiology Reviews Effects of Antiretroviral Therapy on Immunity in Patients Infected with HIV
Current Pharmaceutical Design Structural and Functional Characterization of the Proteins Responsible for N<sup>6</sup>-Methyladenosine Modification and Recognition
Current Protein & Peptide Science Editorial: Signalling Pathways in Virus-caused Cancers
Current Cancer Drug Targets Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Targeted Nanosystems to Prostate Cancer
Current Pharmaceutical Design Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Role of Secondary Alcohol Metabolites in Anthracycline Cardiotoxicity: from Hypotheses to New Drugs
Drug Design Reviews - Online (Discontinued) Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Understanding Mesenchymal Cancer: The Liposarcoma-Associated t(12;16) (q13;;p11) Chromosomal Translocation as a Model
Current Genomics Recent Advances Using Supercritical Fluid Techniques for Pulmonary Administration of Macromolecules via Dry Powder Formulations
Drug Delivery Letters Development of Calixarenes, Cyclodextrins and Fullerenes as New Platforms for Anti-HIV Drug Design: An Overview
Mini-Reviews in Medicinal Chemistry Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets Vesicle Trafficking, Autophagy and Nanoparticles: A Brief Review
Current Nanomedicine Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond
Current Cancer Drug Targets Antibody-Based Imaging of HER-2: Moving into the Clinic
Current Molecular Medicine